Article Text


P44 Assessment Of Spirometry And Impulse Oscillometry In Relation To Asthma Control
  1. A Manoharan,
  2. WJ Anderson,
  3. J Lipworth,
  4. BJ Lipworth
  1. University of Dundee, Dundee, UK


Background Guidelines advocate the use of spirometry to assess pulmonary function in asthmatic patients. Commonly used measures include forced expiratory volume in 1 second (FEV1), forced expiratory ratio (FEV1/FVC) and forced mid-expiratory flow between 25% and 75% of forced vital capacity (FEF25–75). Impulse oscillometry (IOS) is an effort independent test performed during tidal breathing. IOS may be used to assess the total and central airway resistance at 5 Hz (R5) and 20 Hz (R20) respectively and hence derive the peripheral airway resistance from the difference (R5-R20).

Objective To compare spirometry and IOS as tests of global airway function (i.e. FEV1, FEV1/FVC, R5) and putative measures of small airways function (i.e. FEF25–75, R5-R20) and their relationship to long-term asthma control.

Methods Spirometry and IOS measurements from asthmatics were linked to a health informatics database for oral steroid and short-acting beta agonist (SABA) use 1 year prior to the measurements.

Results 442 patients had both spirometry and IOS, mean FEV1= 86% predicted, 94% on ICS, median dose 800 µg/day. IOS and spirometry measures were equally predictive of impaired asthma control for both oral steroid and SABA use. For oral steroid use, the adjusted odds ratio, OR (95% CI): FEV1 <80%: 1.56(0.99–2.47) p = 0.056, FEV1/FVC25–75 <60%: 1.84(1.18–2.86) p = 0.007, R5 >150%: 1.91(1.25–2.95) p = 0.003 and R5-R20 >0.1 kPa·L-1·s 1.73(1.12–2.66) p = 0.013. For SABA use, the adjusted OR (95% CI): FEV1 <80%: 2.22(1.43–3.44) p < 0.001, FEV1/FVC 25–75 <60%: 2.51(1.65–3.82) p < 0.001, R5 >150%: 1.76(1.18–2.63) p = 0.006 and R5-R20 >0.1 kPa·L-1·s: 2.94(1.94–4.46) p.

Conclusion Spirometry or IOS measurements are equally useful as potential markers of asthma control in persistent asthmatic patients.

Abstract P44 Figure 1

Adjusted odds ratios (95% CI) for oral steroid (A) and short-acting beta-agonist use (B) in the year preceding measurements of FEVi (<80% predicted, n = 140 vs >80% predicted, n = 302), FEV1/FVC (<0.70, n = 131 vs >0.70, n = 311), FEF25–75 (<60% predicted, n = 238 vs >60% predicted, n = 204), R5 (>150% predicted, n = 183 vs <150% predicted, n = 259) and R5-R20 (>0.10 kPa-L–1-s, n = 185 vs <0.10 kPa-L–1-s, n = 257). The 95% CIs which exclude unity are defined as being of statistical significance.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.